Depression is a frequent side effect of interferon therapy in patients with chronic Hepatitis C.
Dr Robert Fontana and colleagues from Michigan, USA identified baseline and on-treatment predictors of depression in chronic Hepatitis C patients receiving peginterferon and ribavirin.
The team evaluated 201 prior nonresponders with advanced fibrosis.
The patients were treated with peginterferon alfa-2a and ribavirin for 24 weeks in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial.
Of these, 74 continued on antiviral therapy through week 48.
Mood states were assessed with the Beck Depression Inventory II, and the Composite International Diagnostic Interview.
|22% of patients had baseline depression|
|American Journal of Gastroenterology|
Plasma cortisol and whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72.
The researchers found that the incidence of interferon-induced depression was 23% and 42% at weeks 24 and 48, respectively.
Although 22% of patients had baseline depression, the absence of a week 20 virological response was the only independent predictor of interferon-induced depression at week 24.
The team noted that plasma cortisol levels did not change during treatment nor correlate with depression.
In contrast, whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate with interferon-induced depression through week 24, nor through week 48.
Dr Fontana’s team concluded, “Depression during peginterferon and ribavirin therapy was associated with a lower antiviral response.”
“The significant reduction in whole blood serotonin levels over time suggest that further studies of the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.”